16,472 Shares in Apogee Therapeutics Inc. $APGE Purchased by Mint Tower Capital Management B.V.

Mint Tower Capital Management B.V. purchased a new stake in Apogee Therapeutics Inc. (NASDAQ:APGE) during the 2nd quarter, Holdings Channel reports. The fund purchased 16,472 shares of the company’s stock, valued at approximately $2,186,000.

A number of other large investors have also made changes to their positions in APGE. GAMMA Investing LLC boosted its stake in shares of Apogee Therapeutics by 40.5% during the 2nd quarter. GAMMA Investing LLC now owns 309 shares of the company’s stock worth $41,000 after purchasing an additional 89 shares during the last quarter. Commonwealth Equity Services LLC boosted its holdings in shares of Apogee Therapeutics by 2.2% in the 4th quarter. Commonwealth Equity Services LLC now owns 7,151 shares of the company’s stock valued at $540,000 after purchasing an additional 152 shares during the last quarter. Seven Fleet Capital Management LP increased its stake in Apogee Therapeutics by 9.4% during the first quarter. Seven Fleet Capital Management LP now owns 1,969 shares of the company’s stock worth $166,000 after acquiring an additional 169 shares during the last quarter. Stifel Financial Corp raised its holdings in shares of Apogee Therapeutics by 3.5% in the 4th quarter. Stifel Financial Corp now owns 5,214 shares of the company’s stock worth $394,000 after purchasing an additional 175 shares during the period. Finally, EverSource Wealth Advisors LLC raised its holdings in shares of Apogee Therapeutics by 61.7% in the 1st quarter. EverSource Wealth Advisors LLC now owns 645 shares of the company’s stock worth $54,000 after purchasing an additional 246 shares during the period. Institutional investors and hedge funds own 79.04% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on APGE. Rothschild & Co Redburn assumed coverage on Apogee Therapeutics in a report on Friday, May 1st. They set a “buy” rating and a $140.00 target price for the company. Wedbush lowered shares of Apogee Therapeutics from an “outperform” rating to a “neutral” rating and set a $135.00 price target on the stock. in a report on Monday, June 22nd. Royal Bank Of Canada lifted their price target on shares of Apogee Therapeutics from $82.00 to $97.00 and gave the company a “sector perform” rating in a research report on Monday, June 8th. UBS Group downgraded shares of Apogee Therapeutics from a “buy” rating to a “neutral” rating and boosted their price objective for the stock from $100.00 to $135.11 in a research note on Tuesday, June 23rd. Finally, Mizuho reissued a “neutral” rating and issued a $135.00 target price (up from $110.00) on shares of Apogee Therapeutics in a research note on Wednesday, June 24th. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, fifteen have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $126.77.

Apogee Therapeutics Price Performance

NASDAQ:APGE opened at $134.97 on Friday. The firm has a 50-day moving average of $133.99 and a two-hundred day moving average of $98.55. The stock has a market cap of $8.40 billion, a P/E ratio of -31.10 and a beta of 0.34. Apogee Therapeutics Inc. has a 1-year low of $35.39 and a 1-year high of $134.99.

Apogee Therapeutics (NASDAQ:APGE) last announced its earnings results on Monday, August 10th. The company reported ($1.14) earnings per share for the quarter, missing the consensus estimate of ($1.07) by ($0.07). As a group, equities analysts expect that Apogee Therapeutics Inc. will post -4.47 earnings per share for the current year.

Insider Transactions at Apogee Therapeutics

In related news, CEO Michael Thomas Henderson sold 80,000 shares of the stock in a transaction dated Monday, June 22nd. The stock was sold at an average price of $132.54, for a total value of $10,603,200.00. Following the completion of the transaction, the chief executive officer owned 1,015,987 shares of the company’s stock, valued at approximately $134,658,916.98. This represents a 7.30% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Carl Dambkowski sold 26,400 shares of Apogee Therapeutics stock in a transaction that occurred on Monday, June 22nd. The stock was sold at an average price of $132.60, for a total value of $3,500,640.00. Following the sale, the insider owned 179,248 shares in the company, valued at $23,768,284.80. This represents a 12.84% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 162,900 shares of company stock valued at $20,344,950 in the last three months. 24.30% of the stock is currently owned by company insiders.

About Apogee Therapeutics

Apogee Therapeutics, Inc is a clinical-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics that selectively target the nuclear receptor RORγt, a master regulator of T cell-driven inflammatory pathways. By modulating RORγt activity, Apogee aims to offer an oral treatment option for patients with autoimmune and inflammatory skin disorders.

The company’s lead candidate, APG-157, is an oral RORγt inverse agonist currently undergoing early-stage clinical evaluation for moderate to severe plaque psoriasis.